Your browser does not support JavaScript! PHENOBARBITAL TABLET [CARDINAL HEALTH]
DailyMed Logo Header image

Daily Med

Current Medication Information

Options

RxNorm Names

PHENOBARBITAL tablet
[Cardinal Health]


Category DEA Schedule Marketing Status
HUMAN PRESCRIPTION DRUG LABEL CIV unapproved drug other
NOTE:THIS DRUG HAS NOT BEEN FOUND BY FDA TO BE SAFE AND EFFECTIVE, AND THIS LABELING HAS NOT BEEN APPROVED BY FDA. For further information about unapproved drugs, click here.
Drug Label Sections

PHENOBARBITAL TABLETS, USP
    Rev. 04/04   CIV
         Rx only

DESCRIPTION:
Phenobarbital is a barbituric acid derivative for oral administration and occurs as a white, odorless, slightly bitter powder that is soluble in chloroform, freely soluble in alcohol or ether, and slightly soluble in water. Its saturated solution has a pH of about 5.6. Chemically, it is 5-ethyl-5-phenylbarbituric acid with the molecular formula C12H12N2O3 (232.24). The structural formula is as follows:

Phenobarbital structural formula

Each phenobarbital tablet contains 15 mg, 30 mg, 60 mg or 100 mg of phenobarbital. Inactive ingredients are as follows:
15 mg, 30 and 60 mg: Calcium Stearate, Colloidal Silicon Dioxide, Corn Starch, and Microcrystalline Cellulose.
100 mg: Anhydrous Lactose, Colloidal Silicon Dioxide, Corn Starch, Docusate Sodium, Lactose Monohydrate, Magnesium Stearate, Microcrystalline Cellulose, and Sodium Starch Glycolate.

CLINICAL PHARMACOLOGY:

Phenobarbital, a long-acting barbiturate, is a central nervous system depressant. In ordinary doses, the drug acts as a sedative and anticonvulsant. Its onset of action occurs within 30 minutes, and the duration of action ranges from 5 to 6 hours. It is detoxified in the liver.

INDICATION AND USAGE:

Phenobarbital is indicated for use as a sedative or anticonvulsant.

CONTRAINDICATIONS:

Phenobarbital is contraindicated in patients who are hypersensitive to barbiturates. In such patients, severe hepatic damage can occur from ordinary doses and is usually associated with dermatitis and involvement of parenchymatous organs. A personal or familial history of acute intermittent porphyria represents one of the few absolute contraindications to the use of barbiturates. Phenobarbital is also contraindicated in patients with marked impairment of liver function, or respiratory disease in which dyspnea or obstruction is evident. It should not be administered to persons with known previous addiction to the sedative/hypnotic group, since ordinary doses may be ineffectual and may contribute to further addiction.

WARNINGS:

In small doses, the barbiturates may increase the reaction to painful stimuli. Taken by themselves, the barbiturates cannot be relied upon to relieve pain or even to produce sedation or sleep in the presence of severe pain.

PRECAUTIONS:

General Precautions

Barbiturates induce liver microsomal enzyme activity. This accelerates the biotransformation of various drugs and is probably part of the mechanism of the tolerance encountered with barbiturates. Phenobarbital, therefore, should be used with caution in patients with decreased liver function. This drug should also be administered cautiously to patients with a history of drug dependence or abuse (see DRUG ABUSE AND DEPENDENCE).

Phenobarbital may decrease the potency of coumarin anticoagulants; therefore, patients receiving such concomitant therapy should have more frequent prothrombin determinations. As with other sedatives and hypnotics, elderly or debilitated patients may react to barbiturates with marked excitement, depression, or confusion.

The systemic effects of exogenous hydrocortisone and endogenous hydrocortisone (cortisol) may be diminished by phenobarbital. Thus, this product should be administered with caution to patients with borderline hypoadrenal function, regardless of whether it is of pituitary or of primary adrenal origin.

Information for Patients: 

Phenobarbital may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks, such as driving a car or operating machinery. The patient should be cautioned accordingly.

Drug Interactions:

Phenobarbital in combination with alcohol, tranquilizers, and other central nervous system depressants has additive depressant effects, and the patients should be so advised. Patients taking this drug should be warned not to exceed the dosage recommended by their physician. Toxic effects and fatalities have occurred following overdoses of phenobarbital alone and in combination with other central nervous system depressants. Caution should be exercised in prescribing unnecessarily large amounts of phenobarbital for patients who have a history of emotional disturbances or suicidal ideation or who have misused alcohol and other CNS drugs (see OVERDOSAGE).

Usage in Pregnancy:

Pregnancy Category B – Reproduction studies have been performed in animals and have revealed no evidence of impaired fertility or harm to the fetus due to phenobarbital. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers:

Caution should be exercised when phenobarbital is administered to a nursing woman.

ADVERSE REACTIONS:

The following adverse reactions have been reported:

CNS Depression:

Residual sedation or “hangover”, drowsiness, lethargy, and vertigo. Emotional disturbances and phobias may be accentuated. In some persons, barbiturates such as phenobarbital repeatedly produce excitement rather than depression, and the patient may appear to be inebriated. Like other nonanalgesic hypnotic drugs, barbiturates, such as phenobarbital, when given in the presence of pain, may cause restlessness, excitement, and even delirium. Rarely, the use of barbiturates results in localized or diffused myalgic, neuralgic, or arthritic pain, especially in psychoneurotic patients with insomnia. The pain may appear in paroxysms, is most intense in the early morning hours, and is mot frequently located in the region of the neck, should girdle, and upper limbs. Symptoms may last for days after the drug is discontinued.

Respiratory/Circulatory:

Respiratory depression, apnea, circulatory collapse.

Allergic:

Acquired hypersensitivity to barbiturates consists chiefly in allergic reactions that occur especially in persons who tend to have asthma, urticaria, angioedema, and similar conditions. Hypersensitivity reactions in this category include localized swelling, particularly of the eyelids, cheeks, or lips, and erythematous dermatitis. Rarely, exfoliative dermatitis (e.g., Stevens-Johnson syndrome and toxic epidermal necrolysis) may be caused by phenobarbital and can prove fatal. The skin eruption may be associated with fever, delirium, and marked degenerative changes in the liver and other parenchymatous organs. In a few cases, megaloblastic anemia has been associated with the chronic use of phenobarbital.

Other:

Nausea and vomiting; headache.

DRUG ABUSE AND DEPENDENCE:

Controlled Substance – Phenobarbital is a Schedule IV drug.

Dependence:

Prolonged, uninterrupted use of barbiturates (particularly the short-acting drugs), even in therapeutic doses, may result in psychic and physical dependence. Withdrawal symptoms due to physical dependence following chronic use of large doses of barbiturates may include delirium, convulsions, and death.

OVERDOSAGE:

The signs and symptoms of barbiturate poisoning are referable especially to the central nervous system and the cardiovascular system. Moderate intoxication resembles alcoholic inebriation. In severe intoxication, the patient is comatose, the level of reflex activity conforming in a general way to the intensity of the central depression. The deep reflexes may persist for some time despite coexistent coma. The Babinski sign is often positive. The EEG may be of the “burst-suppression” type, with brief periods of electrical silence. The pupils may be constricted and react to light, but late in the courage of barbiturate poisoning they may show hypoxic paralytic dilatation. Respiration is affected early. Breathing may be either slow or rapid and shallow; Cheyne-Stokes rhythm may be present. Respiratory minute volume is diminished, and hypoxia and respiratory acidosis may develop. The blood pressure falls, owing partly to depression of medullary vasomotor centers; partly to a direct action of the drug on the myocardium, sympathetic ganglia, and vascular smooth muscle; partly to hypoxia.

The patient thus develops a typical shock syndrome, with a weak and rapid pulse, cold and clammy skin, and a rise in the hematocrit. Respiratory complications (atelectasis, pulmonary edema, and bronchopneumonia) and renal failure are much dreaded and not infrequent concomitant of severe barbiturate poisoning. There is usually hypothermia, sometimes with temperatures as low as 32°C.

Treatment:

General management should consist of symptomatic and supportive therapy, including gastric lavage, administration of intravenous fluids, and maintenance of blood pressure, body temperature and adequate respiratory exchange. Dialysis will increase the rate of removal of barbiturates from the body fluids. Antibiotics may be required to control pulmonary complications.

DOSAGE AND ADMINISTRATION:

Oral Sedative Dose, Adults – 30 to 120 mg daily in 2 or 3 divided doses. Children – 6 mg/kg of body weight daily in 3 divided doses.

Oral Hypnotic Dose, Adults – 100 to 320 mg.

Oral Anticonvulsant Dose, Adults – 50 to 100 mg 2 or 3 times daily.

Children – 15 to 50 mg 2 or 3 times daily.

HOW SUPPLIED:

Phenobarbital Tablets USP 15 mg: White, round, unscored, compressed tablet imprinted “West-ward 445”.

      Bottles of 1000 tablets.

Phenobarbital Tablets USP 30 mg: White, round, scored, compressed tablet imprinted “West-ward 450”.

      Bottles of 1000 tablets.
      Bottles of 5000 tablets.

Phenobarbital Tablets USP 60 mg: White, round, unscored, compressed tablet imprinted “WW-455”.

      Bottles of 100 tablets.
      Bottles of 1000 tablets.

Phenobarbital Tablets USP 100 mg: White, round, scored, compressed tablet imprinted “WW-458”.

      Bottles of 100 tablets.
      Bottles of 1000 tablets.

Store at 20-25°C (68-77°F) [See USP Controlled Room Temperature]. Protect from light and moisture.

Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.

West-ward Pharmaceutical Corp.
Eatontown, NJ 07724

Revised April 2004

OR

Hikma Pharmaceuticals

P.O. Box 182400

Amman 11118 - Jordan

Revised April 2004

Phenobarbital Tablets USP 15 mg, 30 mg and 60 mg are available from

Cardinal Health in cards of 30 tablets.

Cardinal Health

Zanesville, OH 43701

OIC8544H0409

Principal Display Panel 1

NDC 0143-1445-10 (West-ward)

Phenobarbital

Tablets USP

15 mg

QTY 30

Phenobarbital 15 mg label front

(Back label 15 mg)

Phenobarbital 15 mg back label

Principal Display Panel 2

NDC 0143-1455-10 (West-ward)

Phenobarbital

Tablets, USP

60 mg

QTY 30

Phenobarbital 60 mg front label Hikma

back label 60 mg

phenobarbital 60 mg back label

Principal Display Panel 3

NDC 0143-1455-10

Phenobarbital

Tablets, USP

60 mg

QTY 30

Phenobarbital 60 mg front label Westward

(Back label 60 mg WW)

Phenobarbital 60 mg back label westward

Principal Display Panel 4

NDC 0143-1450-10 (West-ward)

Phenobarbital

Tablets, USP

30 mg

QTY 30

Phenobarbital 30 mg front label Hikma

back label 30 mg

Phenobarbital 30 mg back label hikma

Phenobarbital 30 mg Westward

NDC 0143-1450-10 (West-ward)

Phenobarbital

Tablets, USP

30 mg

QTY 30

Phenobarbital 30 mg front label westward

back label 30 mg WW

Phenobarbital 30 mg back label Westward

PHENOBARBITAL 
phenobarbital tablet
Product Information
Product TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:55154-7467(NDC:0143-1445)
Route of AdministrationORALDEA ScheduleCIV    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
PHENOBARBITAL (PHENOBARBITAL) PHENOBARBITAL15 mg
Inactive Ingredients
Ingredient NameStrength
CALCIUM STEARATE 
COLLOIDAL SILICON DIOXIDE 
STARCH, CORN 
CELLULOSE, MICROCRYSTALLINE 
Product Characteristics
ColorWHITEScoreno score
ShapeROUNDSize8mm
FlavorImprint Code
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:55154-7467-330 in 1 BLISTER PACK
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
Unapproved drug other01/01/2000
PHENOBARBITAL 
phenobarbital tablet
Product Information
Product TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:55154-7458(NDC:0143-1450)
Route of AdministrationORALDEA ScheduleCIV    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
PHENOBARBITAL (PHENOBARBITAL) PHENOBARBITAL30 mg
Inactive Ingredients
Ingredient NameStrength
CALCIUM STEARATE 
COLLOIDAL SILICON DIOXIDE 
STARCH, CORN 
CELLULOSE, MICROCRYSTALLINE 
Product Characteristics
ColorWHITEScore2 pieces
ShapeROUNDSize9mm
FlavorImprint Code
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:55154-7458-330 in 1 BLISTER PACK
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
Unapproved drug other01/01/2000
PHENOBARBITAL 
phenobarbital tablet
Product Information
Product TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:55154-7457(NDC:0143-1455)
Route of AdministrationORALDEA ScheduleCIV    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
PHENOBARBITAL (PHENOBARBITAL) PHENOBARBITAL60 mg
Inactive Ingredients
Ingredient NameStrength
CALCIUM STEARATE 
COLLOIDAL SILICON DIOXIDE 
STARCH, CORN 
CELLULOSE, MICROCRYSTALLINE 
Product Characteristics
ColorWHITEScoreno score
ShapeROUNDSize9mm
FlavorImprint Code
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:55154-7457-330 in 1 BLISTER PACK
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
Unapproved drug other01/01/2000
Labeler - Cardinal Health (188557102)
Establishment
NameAddressID/FEIBusiness Operations
Cardinal Health188557102REPACK

Revised: 4/2011
 
Cardinal Health

Visit The National Library of Medicine Copyright, Privacy, Accessibility
U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894
National Institutes of Health, Health & Human Services